trending Market Intelligence /marketintelligence/en/news-insights/trending/8yu42afjbe4h_yw_xvszda2 content esgSubNav
In This List

Hybrigenics completes genomics unit buyout as part of strategic shift

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Hybrigenics completes genomics unit buyout as part of strategic shift

Hybrigenics SA completed the previously announced buyout of its unit Helixio, which provides genomic services, by its employees and managers.

Financial terms of the transaction were not disclosed.

The buyout is part of Hybrigenics' strategic refocusing on biopharmaceutical research and development, particularly on anti-cancer drugs. Following the transaction, the Paris-based company and Helixio will operate as fully independent entities.